factually
Index/Topics/Aducanumab Approval 2021

Aducanumab Approval 2021

Aducanumab's accelerated approval by the FDA in 2021 and its controversy

Fact-Checks

2 results
Jan 16, 2026
Most Viewed

Which FDA‑approved therapies exist for early Alzheimer’s disease and what evidence supports their use?

Two biologic therapies have been FDA‑approved to treat early Alzheimer’s disease: lecanemab (Leqembi®) and donanemab (Kisunla™), both monoclonal antibodies that target and clear beta‑amyloid plaques a...

Feb 3, 2026

What are the current FDA‑approved and controversial treatments for Alzheimer’s and their evidence bases?

Two classes of treatments exist today: longstanding symptomatic drugs that modestly delay decline (cholinesterase inhibitors and memantine) and a new wave of anti‑amyloid immunotherapies that reduce b...